NPA CEO Weighs in on CBD, Regulatory RisksNPA CEO Weighs in on CBD, Regulatory Risks
In this video shot at Expo West in Anaheim, California, Daniel Fabricant, Ph.D., of the Natural Products Association weighs in on some of the risks associated with selling CBD in dietary supplements.
May 4, 2018
At Expo West in Anaheim, California, INSIDER caught up with the head of the Natural Products Association (NPA)—Dr. Daniel Fabricant, Ph.D.—to discuss a wide range of topics impacting marketers and retailers of dietary supplements.
In the first of three short video segments, Dr. Fabricant discusses some of the risks associated with selling a hemp-based compound in supplements that has been all the rage in recent years: CBD or cannabidiol. Check out what the former FDA official has to say about CBD.
About the Author(s)
You May Also Like
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023
More bioavailable hyaluronic acid complex for today’s beauty-from-within consumer – snapshotSep 18, 2023